BioSpace News Archive

An article published in Experimental Biology and Medicine details a new therapeutic strategy for obesity and type 2 diabetes.

MD Anderson discovery provides new druggable targets to test against lethal brain tumor

The bankruptcy announcement comes weeks after Insys founder John Kapoor and four former executives were found guilty of orchestrating a kickback scheme to boost sales of its powerful opioid Subsys.

Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.

Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.

Under the terms of the deal, a Merck subsidiary is buying all outstanding shares of Tilos for a total of up to $773 million, including an upfront payment and various potential milestone payments.

The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.

Medtronic plc, the global leader in medical technology, services and solutions, and Tidepool, a 501 nonprofit organization dedicated to making diabetes data more accessible, actionable and meaningful, have agreed to work together to create an interoperable automated insulin pump system.

Despite very positive results, the company’s shares were down 1.5% in premarket trading today. Vamil Divan, an analyst with Credite Suisse, wrote in a note to investors, that results “were fairly consistent across various patient subgroups and are clearly positive” for this class of drug, but “we believe investors may have been hoping for greater risk reduction.”

Trial data showed a two-week course delayed the onset of diabetes by as much as two years in clinical patients.